The Readout Loud
222: Private equity in autism care, a watershed FDA approval, & the future of ALS treatment
This episode isn’t summarized yet
Create a free account and summarize it. In a few minutes you’ll have the key takeaways and a section-by-section summary.
Show notes
First, STAT's Tara Bannow joins us to discuss how private equity's mounting interest in autism care has created an untenable situation for many parents in the U.S. We also explain the implications of Bluebird Bio's long-awaited FDA approval, a controversial treatment for ALS, and the ups and downs of Merck's reported interest in buying Seagen.